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Abstract
Central hypoventilation in adult patients is a rare life-threatening condition characterised by the loss of automatic breathing, 
more pronounced during sleep. In most cases, it is secondary to a brainstem lesion or to a primary pulmonary, cardiac or 
neuromuscular disease. More rarely, it can be a manifestation of congenital central hypoventilation syndrome (CCHS). We 
here describe a 25-year-old woman with severe central hypoventilation triggered by analgesics. Genetic analysis confirmed 
the diagnosis of adult-onset CCHS caused by a heterozygous de novo poly-alanine repeat expansion of the PHOX2B gene. 
She was treated with nocturnal non-invasive ventilation. We reviewed the literature and found 21 genetically confirmed 
adult-onset CCHS cases. Because of the risk of deleterious respiratory complications, adult-onset CCHS is an important 
differential diagnosis in patients with central hypoventilation.
Keywords Central congenital hypoventilation syndrome · PHOX2B · Polyalanine repeat expansion mutation · Hirschsprung 
disease · Neural crest tumours · Autonomic
Key points 
Be aware of LO-CCHS if unexplained hypoventilation.
There might be subtle symptoms indicative of CCHS 
during childhood.
Consider other symptoms, signs and related disorders 
besides hypoventilation.
Consider complete genetic work-up if screening test is 
negative because of the importance of genetic diagnosis 
for patient, offspring and parents.
Longer PARMs or non-PARMs usually have a more 
severe course.
Be aware of the use of respiratory depressant medica-
tions.
CCHS patients don’t outgrow the disorder and require 
lifelong treatment.
CCHS: congenital central hypoventilation syndrome, 
LO-CCHS: later-onset CCHS.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1376 0-020-01363 -w) contains 
supplementary material, which is available to authorized users.
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Introduction
Congenital central hypoventilation syndrome (CCHS, OMIM 
209880) is a rare neurocristopathy, with an estimated incidence 
of 1 in 50,000–200,000 live births [1, 2]. First described in 
1970, the genetic origin was identified by mutations in the 
paired-like homeobox 2B gene (PHOX2B, OMIM 603851) 
[3, 4]. There are about 1000 cases with genetically confirmed 
CCHS reported worldwide, with a male-to-female ratio of 1:1 
[1]. An association with Hirschsprung disease (HSCR) has 
been reported [5]. CCHS is typically characterised by a clas-
sic presentation in newborns and, rarely, a milder later-onset 
(LO-CCHS) presentation in toddlers, children and adults. 
PHOX2B is a transcription factor with expression outside the 
central nervous system restricted to neurons of chromaffin cells 
of the autonomic nervous system expressed by sympathetic, 
parasympathetic and enteric ganglia, adrenal and extra-adrenal 
chromaffin cells and by glomus cells [6]. PHOX2B has a func-
tion in respiratory control and respiratory drive at the level of 
the brainstem [7]. Ninety percent of patients have a heterozy-
gous polyalanine repeat expansion mutation (PARM) within 
exon 3 of PHOX2B, located on chromosome 4p13. Expansions 
of 26 repeats or higher are considered full-penetrance alleles 
[2, 8]. Severe phenotypes in newborns with need for continu-
ous ventilation, association with neural crest tumours, namely 
tumours of the sympathetic nervous system (neuroblastoma, 
ganglioneuroblastoma, ganglioneuroma) and HSCR, as well as 
other functional impairments of the autonomic nervous system 
is seen in patients with longer PARMs or non-PARMs [1, 9, 
10]. The mildest central hypoventilation phenotype is seen in 
patients with repeat lengths of 24 or 25 and presents primarily 
after exposure to respiratory depressants or respiratory infec-
tions, though phenotypes differ across family members carry-
ing the same mutation [1, 11].
Methods
We describe a patient with pharmacologically triggered adult-
onset CCHS and reviewed the literature of adult-onset CCHS. 
Because LO-CCHS is the term used for cases with onset of 
1 month and older, we used LO-CCHS as search term, but 
combined this with search term ‘adult’. 21 cases of LO-CCHS 
with adult-onset are reported. We refer to these cases and our 
novel case as adult-onset CCHS.
Case report
A 25-year-old woman without significant medical history 
was admitted to another hospital because of presumed intox-
ication with paracetamol taken for pain due to premolar root 
canal treatment the day before. Acetylcysteine treatment was 
initiated but no biochemical arguments of hepatic failure 
were revealed. Analgesic treatment with oral oxycodone 
5 mg, oral tramadol 100 mg and intravenous piritramide 
20 mg was given. Subsequently, she developed hypoven-
tilation and loss of consciousness with need for naloxone, 
intubation and sedation with propofol for respiratory sup-
port. During intubation, she experienced two generalised 
tonic–clonic seizures for which levetiracetam was started, 
complicated with aspiration pneumonia. After a few hours, 
she was extubated with persisting hypoventilation and car-
bonarcosis treated with non-invasive ventilation. CT scan 
of the head with angiography and lumbar puncture revealed 
no abnormalities. After 3 days, she was referred to our cen-
tre. History taking revealed complaints of hypersomnolence 
without snoring since months and concentration difficulties 
during studying. Clinical neurological examination was nor-
mal, besides hypersomnolence at time of hypoventilation. 
Questioning her mother, as a child there was a period of cya-
nosis without clear explanation. A curettage was performed 
in 2017 because of missed abortion at 11 weeks.
Arterial blood gas analysis upon admission showed type 
2 respiratory failure [pH 7.25 (7.35–7.45),  PCO2 81 mmHg 
(32–45),  PO2 78 mmHg (83–108), bicarbonate 35 mmol/l 
(22–26)]. Blood ammonia was slightly elevated [58 µmol/l 
(11–48)]. Chest X-ray, electrocardiography, brainstem 
evoked potentials, sympathetic skin response, heart rate vari-
ability, ultrasound of the diaphragm excursions, transtho-
racic echocardiography, spirometry and cerebrospinal fluid 
analysis were normal besides mild dextro-scoliosis. MR scan 
of brain (Fig. 1) revealed an impression from the left verte-
bral artery at the origin of the posterior inferior cerebellar 
artery at the left medulla oblongata without signal alteration 
of the medulla. CT scan of the cervical spine revealed no 
significant changes. Polysomnography was suggestive for 
(central) hypoventilation with hypoxemia and hypercapnia 
(results of the polysomnography are included in the supple-
mentary appendix). Nocturnal capnometry using a Sentec 
Fig. 1  Impression from the left vertebral artery at the origin of the 
posterior inferior cerebellar artery at the left medulla oblongata with-
out signal alteration of the medulla (red arrow) (color figure online)
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Device confirmed nocturnal desaturation until 51% and a 
mean nocturnal  PCO2 of 67 mmHg. Electroencephalography 
was moderately slowed (6.5 Hz), but normalised (9 Hz) after 
non-invasive ventilation as was the case for the arterial blood 
gases. Screening for neoplasia and paraneoplastic syndromes 
was negative. CCHS was considered and genetic analysis 
of PHOX2B, including PCR amplification of all three cod-
ing exons followed by fragment analysis and sequencing, 
was started. This revealed a de novo heterozygous PARM 
of 25 repeats in exon 3 (20/25 genotype) and confirmed the 
diagnosis of CCHS in this patient. There was a delayed and 
inadequate ventilatory response to increasing  PCO2 meas-
ured during wakefulness. After initiation of non-invasive 
ventilation, which leads to a complete night-time  PCO2 cor-
rection, she was discharged for home ventilation 21 days 
after admission. Seventeen months after presentation she is 
doing well on continued treatment.
Congenital central hypoventilation 
syndrome
Diagnostic criteria
Criteria of CCHS, shown in Table 1, have been postulated as 
‘1’ persistent central alveolar hypoventilation during sleep 
detected by polysomnography, while the patient spontane-
ously breathed room air, ‘2’ no primary lung, neuromuscu-
lar, cardiac or brainstem abnormalities that could explain the 
hypoventilation and ‘3’ absent or markedly reduced hyper-
capnic ventilatory response [12, 13]. The requirement of a 
confirmed PHOX2B mutation was added in the American 
Thoracic Society 2009 Policy Statement on CCHS [1, 11]. 
While CCHS is a rare disorder, reports on adult-onset forms 
are even more scarce. A review of the literature revealed 
21 reported genetically confirmed adult-onset CCHS cases, 
summarised in Table 2 and supplementary Table S1 [8, 10, 
11, 14–22].
Pathophysiology
Spontaneous breathing is an automatic process and depends 
on a central pattern generator located in the brainstem 
including neurons in the dorsolateral pons, nucleus of the 
solitary tract and ventrolateral medulla (ventral respiratory 
column). The dorsal respiratory group relays information 
from peripheral chemoreceptors and pulmonary mechanore-
ceptors. The ventral respiratory column controls the activity 
of inspiratory or expiratory motor neurons and contains a 
group of neurons critical for respiratory rhythmogenesis, the 
so-called pre-Bötzinger complex [23]. The retrotrapezoid 
nucleus (RTN), located in the rostral medulla oblongata, 
innervates exclusively the respiratory pattern generator 
neurons. The RTN receives afferent chemosensory informa-
tion and its glutaminergic neurons, that are non-aminergic 
and express homeodomain transcription factor PHOX2B, 
respond vigorously to increases in local  PCO2 [24]. It was 
recently shown that anaesthetic drugs like isoflurane and 
opiates like morphine potentiate aggregation and mislocali-
zation of PHOX2B variants similar to that seen in CCHS. 
These drugs may so hinder folding and activity of proteins 
leading to activation of endoplasmic reticulum stress path-
ways, eventually affecting neuronal function [7]. This effect 
of anaesthetics and opiates may explain their role as a trig-
ger for LO-CCHS in patients carrying a PHOX2B mutation. 
Normally, people can voluntarily alter respiration because 
of higher cortical input to the brainstem. In addition, adult-
onset CCHS patients breathe almost normally. Pre-inspira-
tory potentials generated at the supplementary motor area 
likely play a role in modulation in awake normal humans 
and are significantly more frequent in CCHS patients. These 
findings suggest that the supplementary motor area contrib-
utes to the wakefulness drive to breath by facilitating the 
response of spinal motor neurons to the residual bulbospinal 
drive to breath [25].
Signs, symptoms and neuroimaging
Besides an inadequate response to hypercapnia and hypoxia, 
particularly during sleep, CCHS consists of a broader range 
of symptoms and signs, as well as related diseases (see 
Table 3) [1, 10, 26–28]. In our case series of 22 patients 
with genetically confirmed LO-CCHS, no gastro-intesti-
nal problems were reported. In a case series of 27 CCHS 
patients, gastro-intestinal disorders as dysphagia (4%), 
gastro-intestinal reflux disease (4%) and constipation (15%) 
were seen [29]. Neurological, cardiac, autonomic nervous 
system and dermatological abnormalities were all present 
in our case series. Neurological symptoms were most fre-
quently described with morning headaches in 23%, excessive 
daytime sleepiness or fatigue in 32% and cognitive deficits 
or confusion in 32% of patients. Interestingly, as intellec-
tual and cognitive deficits are described, one study found 
corpus callosum and precuneus thinning, contributing to 
visuospatial deficits and hippocampal–fornix–mamillary 
body injury contributing to temporal cortical thinning with 
resulting deficits in planning and memory. A third cortical 
thinning pattern in the anterior cingulate cortex develops 
from axonal loss of the cingulum bundle and likely contrib-
utes to loss of dyspnoea and to additional affective charac-
teristics in the syndrome, including an impaired sense of 
self-care [26]. Seizures were present in 23% of LO-CCHS 
patients, but another case series reported a higher number 
of CCHS patients with seizures (21/39; 54%) [30]. The most 
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reported cardiac abnormality was cardiac hypertrophy or 
failure in 27% of patients, all males. Blood pressure abnor-
malities, bradycardia and transient asystole were less fre-
quently reported. Gronli JO, et al., reported that r–r interval 
prolongation ≥ 3 s was seen in 38% of CCHS patients. None 
of these patients had PARM 20/25 genotype and there was 
an increasing incidence with increasing repeat length [30]. 
Five patients (23%) had cyanosis and one (4%) had oedema. 
Although strabismus is described in the literature to be pre-
sent in about 50% of CCHS patients, this was not herhalded 
in our case series of LO-CCHS. Also, the prevalence of 
pupillary abnormalities is reported to be as high as 70%, 
Table 2  Criteria of congenital central hypoventilation syndrome [13]
Later-onset congenital central hypoventilation syndrome if presentation after 1 month of life
ANSD autonomic nervous system dysregulation
1 Generally, adequate ventilation while awake and at rest and apparent hypoventilation with monotonous respiratory rate and shallow breathing 
(diminished tidal volume) during sleep OR apparent hypoventilation while both awake and asleep
2 Absent perception of asphyxia (i.e., absent behavioural awareness of hypercapnia and/or hypoxemia) and absent arousal from sleep with 
development of physiologic compromise secondary to hypercapnia and/or hypoxemia
3 Hypoventilation with absent or attenuated ventilatory response to hypercapnia and/or hypoxemia when awake and asleep
4 No evidence of primary neuromuscular, lung, or cardiac disease or identifiable brain stem lesion that could account for the full constellation 
of signs and symptoms including ANSD
5 Confirmed PHOX2B mutation
6 Symptoms of ANSD including but not limited to severe breath-holding spells; lack of physiologic responsiveness to the challenges of exer-
cise and environmental stressors; diminished pupillary light response; oesophageal dysmotility; severe constipation even in the absence of 
Hirschsprung disease; profuse sweating; reduced basal body temperature; and altered perception of anxiety
Table 3  Symptoms and signs
Respiratory Autonomic nervous system dysregulation
Inadequate ventilatory response to hypercapnia and hypoxia Abnormal pupillary light reaction
Hypopneas/apnoea Abnormal sweating pattern
Dyspnoea Abnormal heart-rate variability
Breath-holding spells without air hunger (e.g. abnormal underwater 
swimming capacity)
Impaired glucose homeostasis
Snoring Reduced body basal temperature
Limited breath-to-breath variability Lack of physiological responsiveness to exercise and environmental 
factors
Cardiac Neurological
Attenuated increase in heart rate in response to exercise Daytime sleepiness
Increased frequency of bradycardia and transient asystole, with rhythm 
disturbances severe enough to warrant permanent cardiac pacemaker 
insertion
Fatigue, drowsiness
Confusion
Morning headaches
Decreased heart beat-to-beat variability Altered perception of anxiety
Lower awake and higher asleep blood pressure Seizures
Right heart failure Intellectual and cognitive deficits (visuospatial, planning, memory 
deficits, affective characteristics including impaired sense of self-
care)
cor pulmonale
Gastro-intestinal Facial/dermatological
Oesophageal dysmotility Cyanosis
Dysphagia Swelling/oedema of ankles and feet
Hirschsprung disease Characteristic facies (box-shaped, short and flat)
Biochemical Other
Hypoxia Strabismus
hypercapnia Hypothalamic dysfunction
Polycythaemia Neural crest tumours (neuroblastoma, ganglioneuroblastoma, gangli-
oneuroma)Elevated haematocrit
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but only 9% in the LO-CCHS described here [1]. Given the 
aforementioned symptoms, a list of differential diagnoses 
needs to be considered (see Table 4). 
Associated disorders
HSCR, a congenital malformation of the hindgut which 
occurs as an isolated trait in 70% of cases, but which occa-
sionally is associated with other congenital anomalies, has 
been estimated to be associated with CCHS in 1.5% of 
cases, while 20–50% of patients with CCHS have HSCR 
[27]. HSCR is associated in 19% of CCHS with PARM and 
in 80% of CCHS of non-PARM [28]. None of the 22 adult-
onset CCHS cases were associated with HSCR, but in some 
cases, the disease was present in the offspring [8, 10].
Neural crest tumours (neuroblastoma, ganglioneuro-
blastoma, ganglioneuroma) are present in about 5–10% of 
CCHS. Neuroblastoma estimated risk incidence in CCHS 
with non-PARM is 41–50% and in CCHS with PARM 1% 
[10, 21, 28]. No neural crest tumour in the adult-onset CCHS 
cases or their offspring were seen [8, 10, 11, 14–22].
LO-CCHS in association with hypothalamic dysfunction 
is described in association with a PARM with 25 repeats 
as well as a missense mutation in exon 1 not affecting the 
homeodomain [31]. Other LO-CCHS cases are differentiated 
from rapid-onset obesity with hypothalamic dysfunction, 
hypoventilation, and autonomic dysregulation (ROHHAD) 
syndrome which lack PHOX2B mutations. ROHHAD typi-
cally presents between the ages of 1.5 and 7 years with rapid 
onset obesity [28]. No hypothalamic dysfunction was her-
alded in the listed adult patients [8, 10, 11, 14–22].
Autonomic nervous system disorders (ANSD) have also 
been reported as part of the neurocristopathy. ANSD were 
reported in four adult-onset CCHS cases, including our case, 
namely the non-PARM case and three PARM 20/25 cases. 
Pupillary abnormalities were present in two patients includ-
ing the non-PARM case. One patient had transient asystole 
and two patients had low body temperature, all PARM 20/25 
cases.
Genetics and confirmation of diagnosis
Most of the patients have a heterozygous PARM within exon 
3 of the PHOX2B gene with repeat length ranging from 
24–33, affecting the homeodomain. The normal length is 
20 repeats. Expansion of five alanines is by far the most 
Table 4  Differential diagnosis
LO-CCHS/HD later-onset central hypoventilation syndrome and hypothalamic dysfunction, ROHHAD 
rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syn-
drome
Respiratory
Severe prematurity (apnoea of prematurity)
Acquired hypoventilation
 Obstructive sleep apnoea (e.g. adenotonsillar hypertrophy, obesity, muscle weakness and craniofacial 
anomalies)
Genetic
Paediatric obesity–hypoventilation syndrome (e.g. ROHHAD, Prader–Willi syndrome, LO-CCHS/HD)
Familial dysautonomia (Riley–Day syndrome)
Neurological
Neuromuscular disorder (e.g. paediatric botulism, dystrophia myotonica, myasthenia gravis)
Brainstem lesion
 Infectious or (auto-)immune encephalitis (e.g. bulbar poliomyelitis, syphilis, sarcoidosis of the central 
nervous system)
 Trauma
 Tumour
 Infarction
 Structural abnormality (e.g. os odontoideum, cervical syringomyelia, Chiari type II malformation)
Gastro-intestinal
Aspiration syndromes
Cardiac
 Congestive heart failure
Iatrogenic
Sedative or narcotic overdose
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frequent in LO-CCHS, but other mutations can occur. Ten 
percent of the patients have a non-PARM mutation like a 
missense, a nonsense or more often a frameshift mutation 
[1]. In our case series, a PARM 20/25 is the most common 
mutation in adult-onset CCHS, present in about 80% of all 
cases. In the past, it was suspected that no mutations larger 
than 25 repeats were present in adult-onset cases [21]. In this 
case series, we found a case with a PARM 20/28 mutation as 
well as a PARM 20/24 mutation and one non-PARM associ-
ated with adult-onset CCHS (Fig. 2). Most non-PARM are 
de novo [9, 21]. It is an autosomal dominant disorder with 
reduced penetrance in heterozygous PARM up to 25 repeats 
[2, 8, 18]. Observations argue for a gain-of-function mecha-
nism [8]. Expansions of 26 repeats or higher are considered 
full-penetrance alleles and asymptomatic carriers may only 
be found in association with significant degrees of somatic 
mosaicism [2, 21]. Up to 10(–25)% of unaffected parents 
show somatic mosaicism for the expansion mutation seen in 
the child [17, 21]. Therefore, the recurrence risk of healthy 
individuals carrying an expansion of six repeats can be as 
high as 50%, depending on the unquantifiable extent of their 
germline mosaicism. Polyalanine mutations are transmitted 
unchanged and so are meiotically stable. These mutations 
have also been found to be mitotically stable [2]. There are 
cases in which no PHOX2B mutations are found. Defects 
either impairing correct expression or splicing of the gene, 
or residing outside the transcription unit (position effects) 
are a possible explanation. Genetic heterogeneity could also 
explain the non-mutant patients [31]. However, the exact 
mechanism of inheritance is still unknown. Some mutations 
in PHOX2B can be missed depending on the method for 
molecular genetic analysis. One could perform PCR ampli-
fication of the 20-repeat polyalanine expansion region in 
exon 3 followed by fragment analysis or PCR amplification 
of all three coding exons followed by their sequencing. Frag-
ment analysis can detect polyalanine expansion mutations 
(approximately 90% of PHOX2B mutations) and some non-
PARMs, whereas sequencing can detect expansion mutations 
as well as non-PARMs. However, fragment analysis has the 
advantage of detecting low-level mosaicism, which can be 
helpful for family studies when the proband is known to have 
an expansion mutation, and is, therefore, referred to as the 
PHOX2B screening test [11]. Multiple ligation-dependent 
probe amplification can detect whole gene or exon dele-
tions that are not detected with PHOX2B sequencing [32]. 
A stepwise genetic work-up for PHOX2B testing for an indi-
vidual with central hypoventilation is recommended after 
excluding other explaining disorders. Fragment analysis is 
performed first and if this reveals no mutation, a sequencing 
test is performed. Finally, if no mutation, a multiple ligation-
dependent probe amplification test can be performed [13].
Implications
For the clinical practice
1. Subtle symptoms and signs can be indicative for CCHS 
during childhood. For example unexplained drug-
resistant ‘epilepsy’, cognitive impairment as sequelae 
of hypoxemia and hypercapnia, polycythaemia and right 
ventricular dysfunction [20, 33].
2. As right heart dysfunction can range from mild to life-
threatening cor pulmonale careful evaluation is needed. 
Even CCHS patients with smaller PARMs can have 
severe right heart failure. Cardiac failure alters periph-
eral chemoreceptor sensitivity and so reduces capacity to 
compensate for a blunted central respiratory drive [33].
3. Correct diagnosis is important to reduce complications 
as hypoxia, desaturations, apnoea, seizures, unplanned 
intensive care admissions, prolonged hospital stays and 
long-term need for tracheotomies and ventilation [1].
4. There is an increased risk for sudden infant death syn-
drome or apparent life-threatening episodes [8].
5. Anaesthesiologists need to be aware of undiagnosed 
LO-CCHS especially if unexplained postoperative res-
piratory depression [1]. Other warning signs are a fam-
ily history of CCHS, past history of unusual prolonged 
Fig. 2  Frequency of different PHOX2B mutations in adult-onset con-
genital central hypoventilation syndrome reported in the literature, 
including the presented case. Most mutations concern a heterozygous 
PARM of 5 extra alanine residues (PARM 20/25). One patient was 
reported carrying a ‘mild PHOX2B mutation’ and is represented as 
‘unknown PHOX2B mutation’. PARM polyalanine repeat expansion 
mutation, NPARM non-PARM
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recovery from sedation or anaesthesia or breathing 
pauses at relatively lower concentrations of anaesthet-
ics and a significant decrease of oxygen saturation when 
asleep or in the event of severe respiratory infection [1, 
34].
6. Polysomnography in asymptomatic family members of 
CCHS children is recommended. These individuals can 
be mutation carriers, either germinal or somatic, and 
they should be advised on the increased risk of compli-
cations associated with respiratory infections or the use 
of respiratory depressant drugs [18].
For treatment and drug use
1. Progestins stimulate ventilation and enhance chemosen-
sitivity. Increased levels of progesterone during preg-
nancy do not improve ventilation in CCHS patients. 
There are anecdotal reports on desogestrel 75 µg to 
restore chemosensitivity in CCHS possibly due a higher 
progestin potency value [35].
2. Patients exhibiting only nocturnal hypoventilation 
should usually be treated with nocturnal non-invasive 
bilevel positive airway pressure ventilation. The venti-
lation should be extended to daytime if hypoventilation 
also develops during daytime. In such cases, combina-
tion with diaphragm pacing by phrenic nerve stimu-
lation may be taken into consideration. However, the 
beneficial effect of diaphragm pacing in these patients 
is only reported in some cases and has not been studied 
in controlled trials. For this reason, diaphragm pacing is 
not an evidence-based recommended practice in CCHS 
patients. Home mechanical ventilation via tracheostomy 
is required for younger children for long-term care [34].
3. Anaesthetic techniques should limit respiratory depres-
sant agents and ensure adequate monitoring to detect 
postoperative apnoeas [1]. Non-opioid or local anaes-
thetics are preferred. All anaesthetic drugs should be 
administered by titration to desired effect, preferably 
using short-acting drugs. One should take into account 
the risk of inducing ANSD in CCHS patients. For this 
reason, propofol is not a good choice for the induction 
of anaesthesia or should be used carefully [34].
4. Patients with CCHS require lifelong mechanical ventila-
tion and do not outgrow the disorder [1].
For genotype–phenotype correlation and genetic 
counselling
 1. PARM 20/25 mutations are not fully penetrant. Longer 
PARMs containing 26–33 alanine repeats cause typical 
CCHS and are not associated with variable penetrance 
or adult-onset presentations, though exceptions exist 
[8, 20].
 2. PHOX2B mutations can be in a mosaic state. Patients 
carrying a mosaic mutation are at risk to develop the 
disease [8].
 3. The phenotype tends to be more severe with longer 
PARMs and patients with LO-CCHS harbour only the 
shortest expansions, though exceptions may occur. 
Even a severe CCHS case of the 20/24 has been 
reported without detection of an additional non-PARM 
mutation, although the possibility of mutations in regu-
latory regions of PHOX2B gene or genetic alterations 
in other genes cannot be excluded [8, 11]. PARM 0/24 
or 0/25 present primarily after exposure to respiratory 
depressants or severe respiratory infection [1].
 4. HSCR has been associated with all PHOX2B mutations 
except for PARM 20/25 [34].
 5. Non-PARM mutations increase the risk for tumour 
development. Here also incomplete penetrance and 
somatic mosaicism were hypothesized, because 
approximately 5–10% of healthy parents of patients 
with CCHS were found to harbour a PHOX2B muta-
tion [1].
 6. Longer PARM size has been associated with severity 
of autonomic dysfunction (number of ANSD symp-
toms), increased R-R interval on Holter monitoring, 
severity of ventilatory dependence and predict the need 
for cardiac pacemaker [21, 30].
 7. The specific PHOX2B mutation informs of the severity 
of hypoventilation and the need for ventilation [1].
 8. Parents of CCHS patients should be genetically tested 
to determine the risk of passing the PHOX2B mutation 
and to assess their own risk of requiring mechanical 
ventilation [1].
 9. The recurrence risk of healthy individuals carrying a 
PARM 20/60 can be as high as 50%, depending on the 
unquantifiable extent of their germline mosaicism, a 
circumstance which has to be taken into account in 
genetic counselling to families [2].
 10. As consequence of the challenging use of PCR in 
PHOX2B mutations, an accurate detection of PHOX2B 
mutations is required to make the diagnosis of CCHS 
[1, 11, 36].
 11. Genetic counselling has become indispensable for cou-
ples with an affected child to determine the recurrence 
risk to a fetus [36].
For pregnancy
1. Pregnancy in CCHS patients carries a high risk that 
should be managed preferably at tertiary centres [1].
2. In the normal fetus, modest hypercapnia stimulates 
the amount of time the fetus spends breathing and the 
respiratory rate, while this is not seen in a fetus with 
CCHS. The inability of the respiratory centre to respond 
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to hypercapnia and hypoxemia is inconsequential for the 
fetus but is potentially lethal after birth [37].
3. The level of ventilatory support may need to be adjusted 
as pregnancy progresses for example because of an 
increased respiratory load with enlarging uterus [28].
4. Neonatal support should be available and adequate ven-
tilatory support for a mother with CCHS during labour, 
partus and post-partum period is indicated [1, 28].
5. Parodi et al. mentioned a case of adult-onset CCHS in 
a female with diagnosis at the age of 26 years who had 
two spontaneous abortions [18]. Our case experienced 
a missed abortion, perhaps due to nocturnal hypoxemia.
6. Genetic counselling and prenatal PHOX2B testing for 
the fetus from a CCHS parent should be offered [1, 13, 
37].
For follow‑up
1. In PARM 20/24 and 20/25 mutations annual in-hospital 
comprehensive physiological testing (awake and asleep), 
exogenous and endogenous gas challenges, autonomic 
testing, annual neurocognitive assessment and annual 
72-h Holter recording and TTE are recommended [28].
2. Infants under the age of 3 years should undergo evalua-
tions every 6 months [28].
3. Patients with non-PARM and longer PARM should also 
be screened for HSCR [28].
4. Patients with PARM with a repeat length of 28 or more 
should receive annual imaging to assess for tumours of 
neural crest origin with chest and abdominal imaging 
[28].
5. Non-PARM patients should receive abdominal imaging 
and urine catecholamines every 3 months in the first 
2 years, then every 6 months until 7 years of age [28].
Conclusions
Because of the possible deleterious respiratory conse-
quences, adult-onset CCHS is an important differential 
diagnosis to consider in patients who suffered an episode of 
central hypoventilation and to be aware of regarding phar-
macological therapy in known patients. In case of suspicion, 
genetic analysis of PHOX2B is warranted, given the impor-
tant implications for the clinical practice.
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